迈威（上海）生物科技有限公司 Mediaroom

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical ...

2024-05-13 22:00 1424

FDA Grants Orphan Drug Designation to 9MW2821

SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical c...

2024-05-07 22:00 874

2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

SHANGHAI, April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutica...

2024-04-25 22:00 1029

Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting

SHANGHAI, April 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutica...

2024-04-16 22:00 1311

MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical...

2024-04-08 22:00 1090

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

SHANGHAI, March 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutica...

2024-03-21 14:11 1223

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential

SHANGHAI, March 19, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative-driven biopharmaceutica...

2024-03-19 22:00 1289

Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutica...

2024-03-12 22:00 1560

Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London

SHANGHAI, March 11, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutica...

2024-03-11 22:00 1270

Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer

SHANGHAI, March 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical...

2024-03-08 22:00 1759

FDA Grants Fast Track Designation to 9MW2821

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2024-02-27 22:00 922

Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology

SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2024-02-21 22:00 1320

Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711

SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2024-02-20 22:00 1213

FDA Grants Orphan Drug Designation to 9MW3011

SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2024-02-20 22:00 1215

Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2024-01-02 17:15 1488

New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA

SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-12-19 20:00 1215

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial

SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-12-11 20:00 1099

Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell's 9MW2821 at 2023 ESMO

Shanghai, Oct. 25, 2023 /PRNewswire/ -- ESMO Congress 2023 was held in Madrid, Spain from October 2...

2023-10-25 17:46 1428

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-10-23 18:25 1248

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical comp...

2023-09-28 20:00 1165

Latest News